RT Journal Article SR Electronic T1 Targeted Therapy Followed by Cytotoxic Chemotherapy in Preoperative Patients With Locally Advanced Lung Adenocarcinoma JF Anticancer Research JO Anticancer Res FD International Institute of Anticancer Research SP 2911 OP 2916 DO 10.21873/anticanres.14268 VO 40 IS 5 A1 MASAYA AOKI A1 KAZUHIRO UEDA A1 TADASHI UMEHARA A1 GO KAMIMURA A1 TAKUYA TOKUNAGA A1 AYA HARADA-TAKEDA A1 KOKI MAEDA A1 TOSHIYUKI NAGATA A1 NAOYA YOKOMAKURA A1 KOTA KARIATSUMARI A1 YUTO NONAKA A1 NOBUHIRO IMAMURA A1 SHOICHIRO MORIZONO A1 MASAMI SATO YR 2020 UL http://ar.iiarjournals.org/content/40/5/2911.abstract AB Background: Although oncogene-targeted therapy is a first-line treatment for advanced, unresectable lung adenocarcinoma harboring a target gene mutation, its effect on potentially resectable, locally advanced lung adenocarcinoma remains unclear. Patients and Methods: Ten patients with clinically diagnosed stage III lung adenocarcinoma harboring a target gene mutation were enrolled in the current feasibility study of targeted therapy followed by cytotoxic chemotherapy (platinum and pemetrexed) before radical surgery. Results: Complete resection was accomplished in all nine patients who went on to surgery (one patient refused surgery), and all of these patients recovered without major postoperative complications. Overall, almost all of the patients who underwent surgery remain disease-free after a median follow-up of 22 months since the initial treatment, with only one patient dying of recurrence. Conclusion: Radical surgery after the sequential use of cytostatic and cytotoxic drugs resulted in a favorable short-term outcome.